Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Schoergenhofer

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Internal Medicine|October 30, 2019
PCSK9 decreases during experimental endotoxemiaC Schoergenhofer, P Matzneller, J Mühlbacher, et al.
Journal of Thrombosis and Haemostasis : JTH|September 14, 2016
Dexamethasone inhibits endotoxin-induced coagulopathy in human lungsJ Bartko, C Schoergenhofer, M Schwameis, et al.
European Journal of Internal Medicine|July 1, 2018
Added value of the DIC score and of D-dimer to predict outcome after successfully resuscitated out-of-hospital cardiac arrestN Buchtele, A Schober, C Schoergenhofer, et al.
Frontiers in Pharmacology|August 8, 2022
Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)M Karolyi, E Pawelka, S Omid, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Internal Medicine|October 30, 2019
PCSK9 decreases during experimental endotoxemiaC Schoergenhofer, P Matzneller, J Mühlbacher, et al.
Journal of Thrombosis and Haemostasis : JTH|September 14, 2016
Dexamethasone inhibits endotoxin-induced coagulopathy in human lungsJ Bartko, C Schoergenhofer, M Schwameis, et al.
European Journal of Internal Medicine|July 1, 2018
Added value of the DIC score and of D-dimer to predict outcome after successfully resuscitated out-of-hospital cardiac arrestN Buchtele, A Schober, C Schoergenhofer, et al.
Frontiers in Pharmacology|August 8, 2022
Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)M Karolyi, E Pawelka, S Omid, et al.
Pageof 1